Connecticut-based Alexion Pharmaceuticals, Inc. announced today that the FDA has accepted its supplemental Biologics License Application (sBLA) for SOLIRIS® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. According to Alexion, the submission is supported by phase III data from the REGAIN study.
Eculizumab is a humanized monoclonal antibody currently used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
For more biologics and biosimilar news, stay tuned to Big Molecule Watch.
